Table 4 Univariable and multivariable cox analysis of OS after propensity matched analysis
Variable | Univariable | Univariable | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | P | HR | 95% CI | P | |
Age (≥60/< 60, year) | 0.922 | 0.463–1.837 | 0.818 | – | – | – |
Sex (Men/Women) | 1.458 | 0.689–3.087 | 0.324 | – | – | – |
HBsAg (yes/no) | 1.711 | 0.887–3.300 | 0.109 | – | – | – |
HCV antibody (yes/no) | 6.405 | 1.491–27.524 | 0.013 | 9.142 | 2.028–41.225 | 0.004 |
AFP (≥20/< 20, ng/mL) | 1.288 | 0.761–2.181 | 0.346 | – | – | – |
CEA (≥5/<5, ng/mL) | 1.643 | 0.924–2.923 | 0.091 | – | – | – |
CA19–9 (≥37/<37, U/mL) | 1.591 | 0.932–2.715 | 0.089 | – | – | – |
Liver cirrhosis, yes (%) | 1.952 | 1.091–3.493 | 1.379 | 6.264 | 0.734–2.590 | 0.318 |
TB (≥17/< 17, μmol/L) | 0.739 | 0.383–1.427 | 0.368 | – | – | – |
ALB (≥40/<40, g/mL) | 0.814 | 0.476–1.391 | 0.451 | – | – | – |
ALT (≥35/<35, U/L) | 1.459 | 0.869–2.452 | 0.153 | – | – | – |
γ-GT (≥40/<40, U/L) | 1.811 | 0.933–3.515 | 0.079 | – | – | – |
PLT (≥10/< 10 103/μL) | 1.353 | 0.683–2.682 | 0.386 | – | – | – |
Prothrombin time, median (range), s | 1.014 | 0.547–1.880 | 0.964 | – | – | – |
Tumour size, cm | 1.466 | 0.814–2.639 | 0.203 | – | – | – |
Tumour nodularities | 1.017 | 0.785–1.318 | 0.898 | – | – | – |
Occlusion, min (< 20/≥20) | 1.560 | 0.735–3.310 | 0.247 | – | – | – |
Macrovascular invasion (yes/no) | 3.343 | 1.770–6.315 | < 0.001 | 3.035 | 1.543–5.972 | 0.001 |
Microvascular invasion (yes/no) | 1.359 | 0.725–2.546 | 0.338 | – | – | – |
Lymphoid metastasis (yes/no) | 1.487 | 0.667–3.315 | 0.332 | – | – | – |
Extrahepatic metastasis (yes/no) | 6.805 | 2.549–18.166 | < 0.001 | 6.264 | 2.277–17.235 | < 0.001 |
Preventive TACE (yes/no) | 0.911 | 0.545–1.520 | 0.720 | – | – | – |